| Literature DB >> 18537647 |
Oliver Henschel1, Keith E Gipson, Angelique Bordey.
Abstract
GABA, acting via GABA(A) receptors, is well-accepted as the main inhibitory neurotransmitter of the mature brain, where it dampens neuronal excitability. The receptor's properties have been studied extensively, yielding important information about its structure, pharmacology, and regulation that are summarized in this review. Several GABAergic drugs have been commonly used as anesthetics, sedatives, and anticonvulsants for decades. However, findings that GABA has critical functions in brain development, in particular during the late embryonic and neonatal period, raise worthwhile questions regarding the side effects of GABAergic drugs that may lead to long-term cognitive deficits. Here, we will review some of these drugs in parallel with the control of CNS development that GABA exerts via activation of GABA(A) receptors. This review aims to provide a basic science and clinical perspective on the function of GABA and related pharmaceuticals acting at GABA(A) receptors.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18537647 PMCID: PMC2557552 DOI: 10.2174/187152708784083812
Source DB: PubMed Journal: CNS Neurol Disord Drug Targets ISSN: 1871-5273 Impact factor: 4.388